Form 4: Celldex Therapeutics Executive Acquires 20,000 Stock Options

Ronald Pepin, Senior VP & CBO of Celldex Therapeutics, acquired 20,000 incentive stock options on June 13, 2024, according to a Form 4 filing.

Summary

• Ronald Pepin, the Senior VP & CBO of Celldex Therapeutics, acquired 20,000 incentive stock options on June 13, 2024.
• The options were granted pursuant to the company's 2021 Omnibus Equity Incentive Plan.
• The exercise price of the options is $36.43.
• 25% of the options vest on June 13, 2025, and the remaining options vest quarterly over the subsequent 12 quarters.
• The options expire on June 13, 2034.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The sentiment is neither positive nor negative as it simply reports a transaction.

Positives

• The acquisition of stock options by a company executive can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company executives and their holdings in the company's stock.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Regeneron Pharmaceuticals also utilize stock options as part of their compensation packages to align executive interests with shareholder value.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of executive confidence.

Key Dates